Recombinant Human MMD protein (GST tag N-Terminus)

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Metastasis-Associated in Colon Cancer 1 (MMD) also known as macrophage myristoylated alanine-rich C-kinase substrate (MARCKS) is a protein with a mass of approximately 50 kDa. This protein interacts with the plasma membrane in cells often through binding with acidic phospholipids. MMD primarily expresses in tissues with active cellular signaling such as the brain and immune tissues. It modulates actin cytoskeleton configuration facilitating various cellular processes such as motility and endocytosis.

Biological function summary

This protein plays a role in signaling pathways that regulate cell adhesion and migration. MMD is an integral component in the regulation of cytoskeletal rearrangements which are important for cellular dynamics. MMD functions as part of protein kinase C (PKC) signaling complexes helping modulate cellular responses to external stimuli. By acting as a substrate for PKC MMD influences cellular events that are essential for maintaining cellular structure and function.

Pathways

MMD influences the Protein Kinase C (PKC) pathway and the actin cytoskeleton pathway. It modulates cellular processes key to PKC signal transduction allowing fine-tuning of various physiological responses. PKC-related proteins including MARCKS-related protein (MRP) interact with MMD within these pathways indicating a complex network of interactions facilitating cellular flexibility and responsiveness to environmental changes.

MMD has implications in cancer progression and neurological disorders. MMD dysregulation often correlates with increased metastatic potential in colon cancer indicating its role in tumor cell migration. Additionally abnormalities in MMD expression or function have links to neurodegenerative diseases possibly due to its role in neuronal cell signaling and structure. In these contexts PKC and other interacting proteins contribute to pathological states suggesting therapeutic targets may involve modulating MMD or its pathways.